Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf096 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Tomonori Ishii und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Innovation and Education Center, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Granulomatosis with Polyangiitis, Churg-Strauss Syndrome. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Objectives
Evaluate the long-term safety and effectiveness of mepolizumab in subgroups of patients with eosinophilic granulomatosis with polyangiitis, including: disease duration, oral corticosteroid (OCS) use, relapse, worsening or new-onset symptoms, anti-neutrophil cytoplasm antibodies (ANCA) status, and immunosuppressive therapy use.
Methods
Data from the 96-week MARS study in Japan were analysed for patients receiving mepolizumab for ≥96 weeks, focusing on adverse events (AEs), clinical symptoms, average daily OCS dose, and relapse.
Results
OCS exposure decreased in most subgroups, particularly in the ANCA negative subgroup. Patients on higher average OCS doses (>7.5 mg/day vs ≤7.5 mg/day, during the observation period) experienced more AEs, including infection-related AEs and clinical symptoms, and higher relapse rates. No relapses were observed in patients on an average dose of 0.0 mg/day OCSs. Reduced OCS use was associated with improved clinical outcomes, particularly in patients who remained relapse-free.
Conclusions
Mepolizumab was effective regardless of eosinophilic granulomatosis with polyangiitis duration, ANCA status, or immunosuppressant use. Higher OCS doses were linked to more AEs, clinical symptoms, and relapses compared to lower doses. In relapse-free patients, continued mepolizumab use led to fewer AEs, lower OCS doses, and improved symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Innovation and Education Center, Tohoku University Hospital, Sendai, Japan.
- Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
- Global Real World Evidence and Health Outcomes Research, GSK, Tokyo, Japan.
- Biostatistics, GSK, Tokyo, Japan.
- Medical Affairs, Respiratory, GSK, Tokyo, Japan.
- Global Real World Evidence and Health Outcomes Research, GSK, Collegeville, PA, United States.
Förderung
- GSK
Zitieren
APA
Ishii, T., Kunishige, H., Yoshida, M., Hayashi, E., Komatsubara, M., Alfonso-Cristancho, R., & Howarth, P. (2025). Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf096
Vancouver
Ishii T, Kunishige H, Yoshida M, Hayashi E, Komatsubara M, Alfonso-Cristancho R, et al. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf096
BibTeX
@article{Ishii2025,
author = {Ishii, Tomonori and Kunishige, Hideaki and Yoshida, Mitsuhiro and Hayashi, Etsuko and Komatsubara, Masaki and Alfonso-Cristancho, Rafael and Howarth, Peter},
title = {Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf096}
}
EUVIMED